Research Article

Cadherins Associate with Distinct Stem Cell-Related Transcription Factors to Coordinate the Maintenance of Stemness in Triple-Negative Breast Cancer

Figure 1

Alterations of CDHs in triple-negative breast cancer. (a) Alterations of CDH1, 2, 4, 6, 17, and 26 in TNBC samples from TCGA provisional datasets. The alterations here include deletion, amplification, downregulation, upregulation, and mutations. CDH1 was queried with MUT HOMDEL and other CDHs were queried with default parameters. Microarray data were used for mRNA expression level. The data were retrieved from cBioPortal as of December 15, 2016 (TNBC samples, ). CDH, cadherin; TNBC, triple-negative breast cancer; TCGA, The Cancer Genome Atlas. EXP, mRNA expression level; MUT, mutation; HOMDEL, homozygous deletion; PROT, protein level as determined by reverse phase protein assay (RPPA). (b) Expression of CDH1, 2, 4, and 17 in TNBC compared to non-TNBC samples. These data were retrieved as of December 15, 2016, from Oncomine. Rest indicates non-TNBC samples. For CDH1 (from partial TCGA dataset), TNBC, ; rest, . For CDH2 (from Curtis breast dataset, European Genome-phenome Archive accession number EGAS00000000083), TNBC, ; rest, . For CDH4 (from partial TCGA dataset), TNBC, ; rest, . For CDH17 (from Zhao breast dataset, GEO accession number GSE3971), TNBC, ; rest, . (c) Expression of CDH1, 2, 4, 6, and 17 in CCLE breast cancer cell lines. The expression data (mRNA level) of CDH1, 2, 4, 6, and 17 were retrieved from breast cancer cell lines dataset (GEO accession number GSE36139) by suing CCLE portal according to the instructions. Red represents upregulation; blue means downregulation. The symbol (+) represents triple-negative breast cancer cells, and (+/−) for TNBC-like cells. CCLE, Cancer Cell Line Encyclopedia. (d) Overall survival of TNBC patients with or without CDH1 alterations. TNBC samples () were obtained from TCGA provisional dataset and retrieved with cBioPortal. For CDH1 altered: with median months survival = 33.97; for CDH1 WT: with median months survival = 114.06.
(a)
(b)
(c)
(d)